WHAT IS CLAIMED IS:

1. A compound of Formula I:

$$(R^{4})_{n}$$
 R^{3}
 R^{5}
 R^{1}
 R^{10}
 R^{12}
 R^{13}
 R^{2}
 R^{0x}

5 or a pharmaceutically acceptable salt or stereoisomer thereof,

wherein:

a is 0 or 1;

10 b is 0 or 1;

m is 0, 1, or 2;

n is 0, 1, 2 or 3;

r is 0 or 1;

s is 0 or 1;

15 t is 0, 1 or 2;

20

u is 0 or 1;

R¹ and R² are independently selected from: H, (C₁-C₆)alkyl, aryl, heterocyclyl and (C₃-C₆)cycloalkyl, optionally substituted with one, two or three substituents selected from R⁷;

R³ is selected from:

- 1) hydrogen;
- 2) C₁-C₁₀ alkyl;

- 3) C₁-C₁₀ alkyl-O-R^d,
- 4) C2-C10 alkenyl-O-Rd,
- 5) C2-C10 alkynyl-O-Rd,
- 6) (C₁-C₆-alkylene)_nC₃-C₈ cycloalkyl-O-R^d,
- 5 7) C_1 - C_{10} alkyl- $(C=O)_b$ - NR^cR^c ,
 - 8) C2-C10 alkenyl-(C=O)bNRcRc',
 - 9) C2-C10 alkynyl-(C=O)bNRcRc',
 - 10) (C1-C6-alkylene)_nC3-C8 cycloalkyl-(C=O)_bNR^cR^c',
 - 11) C_1 - C_{10} alkyl- $S(O)_m$ - R^d ,
- 10 12) C_2-C_{10} alkenyl- $S(O)_m-R^d$,
 - 13) C_2 - C_{10} alkynyl- $S(O)_m$ -Rd,
 - 14) (C₁-C₆-alkylene)_nC₃-C₈ cycloalkyl-S(O)_m-R^d,

said alkyl, alkenyl, alkynyl and cycloalkyl are optionally substituted with one or more substituents selected from R⁶;

15

R⁴ is independently selected from:

- 1) $(C=O)_aO_bC_1-C_{10}$ alkyl,
- 2) $(C=O)_aO_baryl$,
- 3) CO₂H,
- 20 4) halo,
 - 5) CN,
 - 6) OH,
 - 7) ObC1-C6 perfluoroalkyl,
 - 8) $O_a(C=O)_bNR^8R^9$,
- 25 9) $S(O)_m R^a$,
 - 10) $S(O)_2NR^8R^9$, and
 - 11) -OPO(OH)₂;

said alkyl, aryl, alkenyl, alkynyl, heterocyclyl, and cycloalkyl optionally substituted with one, two or three substituents selected from R7;

30

R⁵ is selected from:

- 1) hydrogen;
- 2) $(C=O)_aO_bC_1-C_{10}$ alkyl,
- 3) $(C=O)_aO_baryl$,
- 35 4) CO₂H,

- 5) halo,
- 6) CN,
- 7) OH,

5

- 8) ObC1-C6 perfluoroalkyl,
- 9) $O_a(C=O)_bNR^8R^9$,
 - 10) $S(O)_mR^a$,
 - 11) $S(O)_2NR^8R^9$, and
 - 12) -OPO(OH)₂;

said alkyl, aryl, alkenyl, alkynyl, heterocyclyl, and cycloalkyl optionally substituted with one, two or three substituents selected from R⁷;

R⁶ is independently selected from:

- 1) $(C=O)_aO_bC_1-C_{10}$ alkyl,
- 2) $(C=O)_aO_baryl$,
- 15 3) C2-C₁₀ alkenyl,
 - 4) C2-C₁₀ alkynyl,
 - 5) (C=O)_aO_b heterocyclyl,
 - 6) CO₂H,
 - 7) halo,
- 20 8) CN,
 - 9) OH,
 - 10) ObC1-C6 perfluoroalkyl,
 - 11) $O_a(C=O)_bNR^8R^9$,
 - 12) $S(O)_mR^a$,
- 25 13) $S(O)_2NR^8R^9$,
 - 14) oxo,
 - 15) CHO,
 - 16) $(N=0)R^8R^9$,
 - 17) (C=O)aObC3-C8 cycloalkyl, and
- 30 18) –OPO(OH)₂;

said alkyl, aryl, alkenyl, alkynyl, heterocyclyl, and cycloalkyl optionally substituted with one, two or three substituents selected from R⁷;

R⁷ is selected from:

35 1) $(C=O)_TO_S(C_1-C_{10})$ alkyl,

- 2) O_r(C₁-C₃)perfluoroalkyl, 3) oxo, 4) OH, 5) halo, 5 6) CN, 7) (C2-C10)alkenyl, 8) (C2-C10)alkynyl, 9) (C=O)_rO_s(C₃-C₆)cycloalkyl, 10) $(C=O)_rO_s(C_0-C_6)$ alkylene-aryl, 10 11) (C=O)_rO_s(C₀-C₆)alkylene-heterocyclyl, 12) (C=O)_rO_s(C₀-C₆)alkylene-N(R^b)₂, $C(O)R^{a}$ 13) 14) (C0-C6)alkylene-CO2Ra C(O)H, 15) 15 (C0-C6)alkylene-CO2H, and 16) $(C=O)_rN(R^b)_2$, 17) 18) $S(O)_m R^a$, 19) $S(O)_2N(R^b)_2$; and
- said alkyl, alkenyl, alkynyl, cycloalkyl, aryl, alkylene and heterocyclyl is optionally substituted with up to three substituents selected from R^b, OH, (C₁-C₆)alkoxy, halogen, CO₂H, CN, O(C=O)C₁-C₆ alkyl, oxo, NO₂ and N(R^b)₂;

R⁸ and R⁹ are independently selected from:

-OPO(OH)2;

20)

25 1) H, 2) $(C=O)O_bC_1-C_{10}$ alkyl, 3) (C=O)ObC3-C8 cycloalkyl, 4) (C=O)Obaryl, 5) (C=O)Obheterocyclyl, 30 6) C₁-C₁₀ alkyl, 7) aryl, 8) C2-C10 alkenyl, 9) C2-C10 alkynyl, 10) heterocyclyl, 35 11) C3-C8 cycloalkyl,

- 12) SO₂Ra, and
- 13) $(C=O)NRb_2$,

said alkyl, cycloalkyl, aryl, heterocylyl, alkenyl, and alkynyl is optionally substituted with one, two or three substituents selected from R7, or

5

R⁸ and R⁹ can be taken together with the nitrogen to which they are attached to form a monocyclic or bicyclic heterocycle with 3-7 members in each ring and optionally containing, in addition to the nitrogen, one or two additional heteroatoms selected from N, O and S, said monocyclic or bicyclic heterocycle optionally substituted with one, two or three substituents selected from R⁷;

10

R¹⁰ and R¹¹ are independently selected from: F and -CH₂F;

R12 and R13 are independently selected from: H and -CH₂F;

15 R^{ox} is absent or is oxo;

R^a is independently selected from: (C₁-C₆)alkyl, (C₃-C₆)cycloalkyl, aryl, or heterocyclyl, optionally substituted with one, two or three substituents selected from R⁷;

Rb is independently selected from: H, (C₁-C₆)alkyl, aryl, heterocyclyl, (C₃-C₆)cycloalkyl, (C=O)OC₁-C₆ alkyl, (C=O)aryl, (C=O)heterocyclyl, (C=O)NReRe 'or S(O)₂Ra, optionally substituted with one, two or three substituents selected from R⁷;

R^cand R^c' are independently selected from: H, (C₁-C₆)alkyl, aryl, NH₂, OH, OR^a, -(C₁-C₆)alkyl-OH,
(C₁-C₆)alkyl-O-(C₁-C₆)alkyl, (C=O)OC₁-C₆ alkyl, (C=O)C₁-C₆ alkyl, (C=O)aryl, (C=O)heterocyclyl,

(C=O)NR^eR^e', S(O)₂R^a and -(C₁-C₆)alkyl-N(R^b)₂, wherein the alkyl is optionally substituted with one, two or three substituents selected from R⁷; or

R^c and R^c can be taken together with the nitrogen to which they are attached to form a monocyclic or bicyclic heterocycle with 3-7 members in each ring and optionally containing, in addition to the nitrogen, one or two additional heteroatoms selected from N, O and S, said monocyclic or bicyclic heterocycle optionally substituted with one, two or three substituents selected from R⁷;

R^d is selected from: H, (C₁-C₆)alkyl, -(C₂-C₆)alkyl-OH, -(C₁-C₆)alkyl-O-(C₁-C₆)alkyl and -(C₁-C₆)alkyl-N(R^b)₂, wherein the alkyl is optionally substituted with one, two or three substituents selected from R⁷;

Re and Re' are independently selected from: H, (C₁-C₆)alkyl, aryl, heterocyclyl and (C₃-C₆)cycloalkyl, optionally substituted with one, two or three substituents selected from R⁷; or

Re and Re' can be taken together with the nitrogen to which they are attached to form a monocyclic or bicyclic heterocycle with 3-7 members in each ring and optionally containing, in addition to the nitrogen, one or two additional heteroatoms selected from N, O and S, said monocyclic or bicyclic heterocycle optionally substituted with one, two or three substituents selected from R⁷.

2. The compound according to Claim 1 of Formula II:

or a pharmaceutically acceptable salt or stereoisomer thereof,

wherein:

10

a is 0 or 1;
20 b is 0 or 1;
m is 0, 1, or 2;
n is 0, 1, 2 or 3;
r is 0 or 1;

```
s is 0 or 1;
t is 0 or 1;
```

R¹ and R² are independently selected from: H, (C₁-C₆)alkyl, aryl, heterocyclyl and (C₃-C₆)cycloalkyl, optionally substituted with one, two or three substituents selected from R⁷;

R³ is selected from:

- 1) hydrogen;
- 2) C₁-C₁₀ alkyl;
- 10 3) C₁-C₁₀ alkyl-O-Rd,
 - 4) C2-C10 alkenyl-O-Rd,
 - 5) C2-C₁₀ alkynyl-O-R^d,
 - 6) (C₁-C₆-alkylene)_nC₃-C₈ cycloalkyl-O-Rd,
 - 7) C_1 - C_{10} alkyl- $(C=O)_b$ -NRCRC',
- 15 8) C_2 - C_{10} alkenyl- $(C=O)_bNR^cR^c$,
 - 9) C2-C₁₀ alkynyl-(C=O)_bNRcRc',
 - 10) (C₁-C₆-alkylene)_nC₃-C₈ cycloalkyl-(C=O)_bNRcRc',
 - 11) C_1 - C_{10} alkyl- $S(O)_m$ -Rd,
 - 12) C_2 - C_{10} alkenyl- $S(O)_m$ -Rd,
- 20 13) C2-C₁₀ alkynyl- S(O)_m-Rd,
 - 14) (C₁-C₆-alkylene)_nC₃-C₈ cycloalkyl-S(O)_m-Rd,

said alkyl, alkenyl, alkynyl and cycloalkyl are optionally substituted with one or more substituents selected from R6;

- 25 R⁴ is independently selected from:
 - 1) $(C=O)_aO_bC_1-C_{10}$ alkyl,
 - 2) (C=O)_aO_baryl,
 - 3) CO₂H,
 - 4) halo,
 - 5) CN,

30

- 6) OH,
- 7) ObC1-C6 perfluoroalkyl,
- 8) $O_a(C=O)_bNR^8R^9$,
- 9) $S(O)_mR^a$,
- 35 10) $S(O)_2NR^8R^9$,

said alkyl, aryl, alkenyl, alkynyl, heterocyclyl, and cycloalkyl optionally substituted with one, two or three substituents selected from R⁷;

R⁵ is selected from:

- 5 1) hydrogen;
 - 2) $(C=O)_aO_bC_1-C_{10}$ alkyl,
 - 3) (C=O)_aO_baryl,
 - 4) CO₂H,
 - 5) halo,
- 10 6) CN,
 - 7) OH,
 - 8) ObC1-C6 perfluoroalkyl,
 - 9) $O_a(C=O)_bNR^8R^9$,
 - 10) $S(O)_m R^a$,
- 15 11) $S(O)_2NR^8R^9$, and
 - 12) –OPO(OH)₂;

said alkyl, aryl, alkenyl, alkynyl, heterocyclyl, and cycloalkyl optionally substituted with one, two or three substituents selected from R7;

- 20 R⁶ is independently selected from:
 - 1) $(C=O)_aO_bC_1-C_{10}$ alkyl,
 - 2) (C=O)_aO_baryl,
 - 3) C2-C₁₀ alkenyl,
 - 4) C2-C₁₀ alkynyl,
- 25 5) (C=O)_aO_b heterocyclyl,
 - 6) CO₂H,
 - 7) halo,
 - 8) CN,
 - 9) OH,
- 30 10) ObC1-C6 perfluoroalkyl,
 - 11) $O_a(C=O)_bNR^8R^9$,
 - 12) $S(O)_mR^a$,
 - 13) $S(O)_2NR^8R^9$,
 - 14) oxo,
- 35 15) CHO,

- 16) $(N=0)R^8R^9$,
- 17) (C=O)_aO_bC₃-C₈ cycloalkyl, and
- 18) -OPO(OH)₂;

said alkyl, aryl, alkenyl, alkynyl, heterocyclyl, and cycloalkyl optionally substituted with one, two or three substituents selected from R⁷;

R⁷ is selected from:

- 1) $(C=O)_{r}O_{s}(C_{1}-C_{10})$ alkyl,
- 2) O_r(C₁-C₃)perfluoroalkyl,
- 10 3) oxo,
 - 4) OH,
 - 5) halo,
 - 6) CN,
 - 7) (C2-C10)alkenyl,
- 15 8) (C₂-C₁₀)alkynyl,
 - 9) $(C=O)_rO_s(C_3-C_6)$ cycloalkyl,
 - 10) $(C=O)_rO_s(C_0-C_6)$ alkylene-aryl,
 - 11) (C=O)_rO_s(C₀-C₆)alkylene-heterocyclyl,
 - 12) $(C=O)_rO_s(C_0-C_6)$ alkylene- $N(R^b)_2$,
- 20 13) C(O)Ra,
 - 14) (C₀-C₆)alkylene-CO₂R^a,
 - 15) C(O)H,
 - 16) (C₀-C₆)alkylene-CO₂H,
 - 17) $C(O)N(R^b)_2$,
- 25 18) $S(O)_m R^a$,

30

- 19) $S(O)_2N(R^b)_2$; and
- 20) $-OPO(OH)_2$;

said alkyl, alkenyl, alkynyl, cycloalkyl, aryl, alkylene and heterocyclyl is optionally substituted with up to three substituents selected from R^b, OH, (C₁-C₆)alkoxy, halogen, CO₂H, CN, O(C=O)C₁-C₆ alkyl, oxo, NO₂ and N(R^b)₂;

R8 and R9 are independently selected from:

- 1) H,
- 2) (C=O)ObC1-C10 alkyl,
- 35 3) (C=O)ObC3-C8 cycloalkyl,

- (C=O)Obaryl, 4)
- (C=O)Obheterocyclyl, 5)
- C1-C10 alkyl, 6)
- aryl, 7)
- C2-C10 alkenyl, 8) 5
 - C2-C10 alkynyl, 9)
 - heterocyclyl, 10)
 - C3-C8 cycloalkyl, 11)
 - SO₂Ra, and 12)
- (C=O)NRb2, 10

said alkyl, cycloalkyl, aryl, heterocylyl, alkenyl, and alkynyl is optionally substituted with one, two or three substituents selected from R7, or

R8 and R9 can be taken together with the nitrogen to which they are attached to form a monocyclic or bicyclic heterocycle with 3-7 members in each ring and optionally containing, in addition to the nitrogen, one or two additional heteroatoms selected from N, O and S, said monocyclic or bicyclic heterocycle 15 optionally substituted with one, two or three substituents selected from R7;

R10 is selected from: F and -CH2F;

20

30

R13 is selected from: H and -CH2F, provided that if t is 1, R13 is H;

Rox is absent or is oxo;

 $R^{\dot{a}}$ is independently selected from: (C1-C6)alkyl, (C3-C6)cycloalkyl, aryl, or heterocyclyl, optionally 25 substituted with one, two or three substituents selected from R7;

Rb is independently selected from: H, (C1-C6)alkyl, aryl, heterocyclyl, (C3-C6)cycloalkyl, (C=O)OC1- $C_6 \ alkyl, (C=O)C_1-C_6 \ alkyl, (C=O)aryl, (C=O)heterocyclyl, (C=O)NR^eR^{e'} or \ S(O)_2R^a, optionally \ S(O)_2R^a, opt$ substituted with one, two or three substituents selected from R7;

R^cand R^c' are independently selected from: H, (C₁-C₆)alkyl, aryl, NH₂, OH, OR^a, -(C₁-C₆)alkyl-OH, - $(C_1-C_6) alkyl-O-(C_1-C_6) alkyl, (C=O)OC_1-C_6 alkyl, (C=O)C_1-C_6 alkyl, (C=O) aryl, (C=O) heterocyclyl, (C=O) alkyl-O-(C_1-C_6) alkyl, (C=O)OC_1-C_6 alkyl, (C=O)OC_1-C_6$ (C=O)NReRe ', $S(O)_2R^a$ and -(C1-C6)alkyl-N(R^b)2, wherein the alkyl is optionally substituted with one,

two or three substituents selected from R7; or 35

5

10

20

R^c and R^c' can be taken together with the nitrogen to which they are attached to form a monocyclic or bicyclic heterocycle with 3-7 members in each ring and optionally containing, in addition to the nitrogen, one or two additional heteroatoms selected from N, O and S, said monocyclic or bicyclic heterocycle optionally substituted with one, two or three substituents selected from R⁷;

Rd is selected from: H, (C₁-C₆)alkyl, -(C₂-C₆)alkyl-OH, -(C₁-C₆)alkyl-O-(C₁-C₆)alkyl and -(C₁-C₆)alkyl-N(R^b)₂, wherein the alkyl is optionally substituted with one, two or three substituents selected from R⁷;

Re and Re' are independently selected from: H, (C₁-C₆)alkyl, aryl, heterocyclyl and (C₃-C₆)cycloalkyl, optionally substituted with one, two or three substituents selected from R⁷; or

Re and Re' can be taken together with the nitrogen to which they are attached to form a monocyclic or bicyclic heterocycle with 3-7 members in each ring and optionally containing, in addition to the nitrogen, one or two additional heteroatoms selected from N, O and S, said monocyclic or bicyclic heterocycle optionally substituted with one, two or three substituents selected from R⁷.

3. The compound according to Claim 2 of the Formula III:

(R⁴)n
OH
N
OH
N
R⁵

or a pharmaceutically acceptable salt or stereoisomer thereof,

wherein:

```
a is 0 or 1;
```

b is 0 or 1;

5 m is 0, 1, or 2;

n is 0, 1 or 2;

r is 0 or 1;

s is 0 or 1;

10 R¹ and R² are independently selected from: H, (C₁-C₆)alkyl, aryl and (C₃-C₆)cycloalkyl, optionally substituted with one, two or three substituents selected from R⁷;

R4 is independently selected from:

- 1) halo,
- 15 2) OH,
 - 3) ObC1-C6 perfluoroalkyl,

R⁵ is selected from:

- 1) hydrogen,
- 20 2) halo,
 - 3) OH,
 - 4) ObC₁-C₆ perfluoroalkyl,

R7 is selected from:

- 25 1) $(C=O)_rO_s(C_1-C_{10})$ alkyl,
 - 2) O_r(C₁-C₃)perfluoroalkyl,
 - 3) oxo,
 - 4) OH,
 - 5) halo,
- 30 6) CN,
 - 7) (C₂-C₁₀)alkenyl,
 - 8) (C_2-C_{10}) alkynyl,
 - 9) $(C=O)_rO_s(C_3-C_6)$ cycloalkyl,
 - 10) $(C=O)_TO_S(C_0-C_6)$ alkylene-aryl,
- 35 (C=O)_rO_s(C0-C6)alkylene-heterocyclyl,

- 12) $(C=O)_rO_s(C_0-C_6)$ alkylene- $N(R^b)_2$,
- 13) $C(O)R^{a}$,
- 14) (C₀-C₆)alkylene-CO₂R^a,
- 15) C(O)H,

5

- 16) (C₀-C₆)alkylene-CO₂H, and
 - 17) $C(O)N(R^b)_2$,
 - 18) $S(O)_mR^a$, and
 - 19) $S(O)_2N(R^b)_2$;

said alkyl, alkenyl, alkynyl, cycloalkyl, aryl, alkylene and heterocyclyl is optionally substituted with up to three substituents selected from R^b, OH, (C₁-C₆)alkoxy, halogen, CO₂H, CN, O(C=O)C₁-C₆ alkyl, oxo, NO₂ and N(R^b)₂;

R8 and R9 are independently selected from:

- 1) H,
- 15 2) (C=O)O_bC₁-C₁₀ alkyl,
 - 3) (C=O)ObC3-C8 cycloalkyl,
 - 4) (C=O)Obaryl,
 - 5) (C=O)Obheterocyclyl,
 - 6) C_1 - C_{10} alkyl,
- 20 7) aryl,
 - 8) C₂-C₁₀ alkenyl,
 - 9) C₂-C₁₀ alkynyl,
 - 10) heterocyclyl,
 - 11) C3-C8 cycloalkyl,
- 25 12) SO₂R^a, and
 - 13) $(C=O)NRb_2$,

said alkyl, cycloalkyl, aryl, heterocylyl, alkenyl, and alkynyl is optionally substituted with one, two or three substituents selected from R7, or

R8 and R9 can be taken together with the nitrogen to which they are attached to form a monocyclic or bicyclic heterocycle with 3-7 members in each ring and optionally containing, in addition to the nitrogen, one or two additional heteroatoms selected from N, O and S, said monocyclic or bicyclic heterocycle optionally substituted with one, two or three substituents selected from R7;

R^a is independently selected from: (C₁-C₆)alkyl, (C₃-C₆)cycloalkyl, aryl, or heterocyclyl, optionally substituted with one, two or three substituents selected from R⁷;

Rb is independently selected from: H, (C₁-C₆)alkyl, aryl, heterocyclyl, (C₃-C₆)cycloalkyl, (C=O)OC₁-C₆ alkyl, (C=O)aryl, (C=O)heterocyclyl, (C=O)NReRe 'or S(O)₂Ra, optionally substituted with one, two or three substituents selected from R⁷;

R^c and R^c are independently selected from: H, (C₁-C₆)alkyl, aryl, NH₂, OH, OR^a, -(C₁-C₆)alkyl-OH, - (C₁-C₆)alkyl-O-(C₁-C₆)alkyl, (C=O)OC₁-C₆ alkyl, (C=O)Aryl, (C=O)heterocyclyl, (C=O)NR^eR^e, S(O)₂R^a and -(C₁-C₆)alkyl-N(R^b)₂, wherein the alkyl is optionally substituted with one, two or three substituents selected from R⁷; or

10

15

25

R^c and R^c can be taken together with the nitrogen to which they are attached to form a monocyclic or bicyclic heterocycle with 3-7 members in each ring and optionally containing, in addition to the nitrogen, one or two additional heteroatoms selected from N, O and S, said monocyclic or bicyclic heterocycle optionally substituted with one, two or three substituents selected from R⁷;

Re and Re' are independently selected from: H, (C₁-C₆)alkyl, aryl, heterocyclyl and (C₃-C₆)cycloalkyl, optionally substituted with one, two or three substituents selected from R⁷; or

20 Re and Re' can be taken together with the nitrogen to which they are attached to form a monocyclic or bicyclic heterocycle with 3-7 members in each ring and optionally containing, in addition to the nitrogen, one or two additional heteroatoms selected from N, O and S, said monocyclic or bicyclic heterocycle optionally substituted with one, two or three substituents selected from R⁷.

4. The compound according to Claim 3 of the Formula IV:

or a pharmaceutically acceptable salt or stereoisomer thereof,

wherein:

5

a is 0 or 1;

b is 0 or 1;

m is 0, 1, or 2;

r is 0 or 1;

10 s is 0 or 1;

 R^1 and R^2 are independently selected from: H and (C₁-C₆)alkyl, optionally substituted with one, two or three substituents selected from R^7 ;

- 15 R⁴ is independently selected from:
 - 1) halo,
 - 2) OH,
 - 3) ObC1-C6 perfluoroalkyl,
- 20 R⁷ is selected from:
 - 1) $(C=O)_rO_s(C_1-C_{10})$ alkyl,
 - 2) O_r(C₁-C₃)perfluoroalkyl,
 - 3) oxo,
 - 4) OH,
- 25 5) halo,

- 6) CN,
- 7) (C2-C10)alkenyl,
- 8) (C2-C10)alkynyl,
- 9) $(C=O)_TO_S(C_3-C_6)$ cycloalkyl,
- 5 $(C=O)_rO_s(C_0-C_6)$ alkylene-aryl,
 - 11) (C=O)_rO_S(C₀-C₆)alkylene-heterocyclyl,
 - 12) $(C=O)_rO_s(C_0-C_6)$ alkylene- $N(R^b)_2$,
 - 13) $C(O)R^{a}$,
 - 14) (C₀-C₆)alkylene-CO₂R^a,
- 10 15) C(O)H,
 - 16) (C₀-C₆)alkylene-CO₂H, and
 - 17) $C(O)N(R^b)_2$,
 - 18) $S(O)_mR^a$, and
 - 19) $S(O)_2N(R^b)_2$;
- said alkyl, alkenyl, alkynyl, cycloalkyl, aryl, alkylene and heterocyclyl is optionally substituted with up to three substituents selected from R^b, OH, (C₁-C₆)alkoxy, halogen, CO₂H, CN, O(C=O)C₁-C₆ alkyl, oxo, NO₂ and N(R^b)₂;

R⁸ and R⁹ are independently selected from:

- 20 1) H,
 - 2) $(C=O)O_bC_1-C_{10}$ alkyl,
 - 3) (C=O)O_bC₃-C₈ cycloalkyl,
 - 4) (C=O)Obaryl,
 - 5) (C=O)Obheterocyclyl,
- 25 6) C₁-C₁₀ alkyl,
 - 7) aryl,
 - 8) C₂-C₁₀ alkenyl,
 - 9) C2-C₁₀ alkynyl,
 - 10) heterocyclyl,
- 30 11) C₃-C₈ cycloalkyl,
 - 12) SO₂R^a, and
 - 13) $(C=O)NRb_2$,

said alkyl, cycloalkyl, aryl, heterocylyl, alkenyl, and alkynyl is optionally substituted with one, two or three substituents selected from R⁷, or

35

R8 and R9 can be taken together with the nitrogen to which they are attached to form a monocyclic or bicyclic heterocycle with 3-7 members in each ring and optionally containing, in addition to the nitrogen, one or two additional heteroatoms selected from N, O and S, said monocyclic or bicyclic heterocycle optionally substituted with one, two or three substituents selected from R7;

5

. 15

20

25

30

R^a is independently selected from: (C₁-C₆)alkyl, (C₃-C₆)cycloalkyl, aryl, or heterocyclyl, optionally substituted with one, two or three substituents selected from R⁷;

Rb is independently selected from: H, (C₁-C₆)alkyl, aryl, heterocyclyl, (C₃-C₆)cycloalkyl, (C=O)OC₁-C₆ alkyl, (C=O)C₁-C₆ alkyl, (C=O)aryl, (C=O)heterocyclyl, (C=O)NReRe 'or S(O)₂Ra, optionally substituted with one, two or three substituents selected from R7;

R^cand R^c ' are independently selected from: H, (C₁-C₆)alkyl, aryl, NH₂, OH, OR^a, -(C₁-C₆)alkyl-OH, - (C₁-C₆)alkyl-O-(C₁-C₆)alkyl, (C=O)OC₁-C₆ alkyl, (C=O)C₁-C₆ alkyl, (C=O)aryl, (C=O)heterocyclyl, (C=O)NReRe', S(O)₂R^a and -(C₁-C₆)alkyl-N(R^b)₂, wherein the alkyl is optionally substituted with one, two or three substituents selected from R⁷; or

Rc and Rc' can be taken together with the nitrogen to which they are attached to form a monocyclic or bicyclic heterocycle with 3-7 members in each ring and optionally containing, in addition to the nitrogen, one or two additional heteroatoms selected from N, O and S, said monocyclic or bicyclic heterocycle optionally substituted with one, two or three substituents selected from R⁷;

Re and Re' are independently selected from: H, (C₁-C₆)alkyl, aryl, heterocyclyl and (C₃-C₆)cycloalkyl, optionally substituted with one, two or three substituents selected from R⁷; or

Re and Re' can be taken together with the nitrogen to which they are attached to form a monocyclic or bicyclic heterocycle with 3-7 members in each ring and optionally containing, in addition to the nitrogen, one or two additional heteroatoms selected from N, O and S, said monocyclic or bicyclic heterocycle optionally substituted with one, two or three substituents selected from R⁷.

5. The compound according to Claim 4 of the Formula V:

or a pharmaceutically acceptable salt or stereoisomer thereof,

wherein:

5

 ${\rm R}^1$ and ${\rm R}^2$ are independently selected from: H and (C1-C6)alkyl.

6. The compound according to Claim 2 of the formula VI:

10 or a pharmaceutically acceptable salt or stereoisomer thereof,

wherein:

R¹ and R² are independently selected from: H and (C₁-C₆)alkyl.

15

7. A compound selected from:

- (2S)-4-(2,5-Difluorophenyl)-N-[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]-2-(hydroxymethyl)-N-methyl-2-phenyl-2,5-dihydro-1H-pyrrole-1-carboxamide
- (2S)-4-(2,5-Difluorophenyl)-N-[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]-2-(hydroxymethyl)-N-methyl-2-phenyl-2,5-dihydro-1*H*-pyrrole-1-carboxamide
- (2S)-4-(2,5-Difluorophenyl)-N-[(3R,4R)-3-fluoro-1-methylpiperidin-4-yl]-2-(hydroxymethyl)-N-methyl-10 2-phenyl-2,5-dihydro-1H-pyrrole-1-carboxamide
 - (2*S*)-4-(2,5-Difluorophenyl)-*N*-[(3*S*,4*S*)-3-fluoro-1-methylpiperidin-4-yl]-2-(hydroxymethyl)-*N*-methyl-2-phenyl-2,5-dihydro-1*H*-pyrrole-1-carboxamide
- 15 (2S)-4-(2,5-Difluorophenyl)-*N*-[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]-*N*-methyl-2-phenyl-2,5-dihydro-1*H*-pyrrole-1-carboxamide
 - (2S)-4-(2,5-Difluorophenyl)-N-[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]-N-methyl-2-phenyl-2,5-dihydro-1H-pyrrole-1-carboxamide
 - (2S)-4-(2,5-Difluorophenyl)-N-[(3R,4R)-3-fluoro-1-methylpiperidin-4-yl]-N-methyl-2-phenyl-2,5-dihydro-1H-pyrrole-1-carboxamide
- (2S)-4-(2,5-Difluorophenyl)-N-[(2R,4R)-2-(fluoromethyl)-1-methylpiperidin-4-yl]-2-(hydroxymethyl)-N-25 methyl-2-phenyl-2,5-dihydro-1*H*-pyrrole-1-carboxamide
 - (2S)-4-(2,5-Difluorophenyl)-*N*-[(2S,4S)-2-(fluoromethyl)-1-methylpiperidin-4-yl]-2-(hydroxymethyl)-*N*-methyl-2-phenyl-2,5-dihydro-1*H*-pyrrole-1-carboxamide
- 30 (2S)-4-(2,5-Difluorophenyl)-N-[(3S,4R)-3-fluoro-1-methyl-1-oxidopiperidin-4-yl]-2-(hydroxymethyl)-N-methyl-2-phenyl-2,5-dihydro-1H-pyrrole-1-carboxamide
 - (2*S*)-4-(2,5-Difluorophenyl)-*N*-[(3*S*,4*R*)-3-fluoropiperidin-4-yl]-2-(hydroxymethyl)-*N*-methyl-2-phenyl-2,5-dihydro-1*H*-pyrrole-1-carboxamide

35

5

20

 $(2S)-4-(2,5-\text{Difluorophenyl})-N-[(3S,4R)-3-\text{fluoro-1-isopropylpiperidin-4-yl}]-2-(\text{hydroxymethyl})-N-\text{methyl-2-phenyl-2,5-dihydro-1}\\ H-\text{pyrrole-1-carboxamide}$

(2S)-4-(2,5-Difluorophenyl)-*N*-[(3S,4S)-3-fluoropiperidin-4-yl]-2-(hydroxymethyl)-*N*-methyl-2-phenyl-2,5-dihydro-1*H*-pyrrole-1-carboxamide

or a pharmaceutically acceptable salt thereof.

8. A compound which is:

10

5

 $(2S)-4-(2,5-\text{Difluorophenyl})-N-[(3S,4S)-3-\text{fluoro-1-methylpiperidin-4-yl}]-2-(\text{hydroxymethyl})-N-\text{methyl-2-phenyl-2,5-dihydro-1}\\ H-\text{pyrrole-1-carboxamide}$

or a pharmaceutically acceptable salt thereof.

15

9. A compound which is:

 $(2S)-4-(2,5-\text{Difluorophenyl})-N-[(3S,4R)-3-\text{fluoro-1-methylpiperidin-4-yl}]-2-(\text{hydroxymethyl})-N-\text{methyl-2-phenyl-2,5-dihydro-1}\\ H-\text{pyrrole-1-carboxamide}$

- 5 or a pharmaceutically acceptable salt thereof.
 - 10. A compound which is:

(2*S*)-4-(2,5-Difluorophenyl)-*N*-[(3*R*,4*S*)-3-fluoro-1-methylpiperidin-4-yl]-2-(hydroxymethyl)-*N*-methyl-2-10 phenyl-2,5-dihydro-1*H*-pyrrole-1-carboxamide

or a pharmaceutically acceptable salt thereof.

11. A compound which is:

(2S)-4-(2,5-Difluorophenyl)-N-[(2R,4R)-2-(fluoromethyl)-1-methylpiperidin-4-yl]-2-(hydroxymethyl)-N-methyl-2-phenyl-2,5-dihydro-1H-pyrrole-1-carboxamide

5 or a pharmaceutically acceptable salt thereof.

12. A compound which is:

(2S)-4-(2,5-Difluorophenyl)-N-[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]-N-methyl-2-phenyl-2,5-dihydro-1H-pyrrole-1-carboxamide

or a pharmaceutically acceptable salt thereof.

13. The compound according to Claim 1 selected from:

$$R_4$$
 R_5
 R_5
 R_2
 R_3
 R_4
 R_5
 R_5
 R_5
 R_5

	• • • •			
R ₁	R ₂	R ₃	R ₄	R ₅
^	CH₂OH	Me	F	н
//	CH₂OH	Ме	F	н
	CH ₂ OH	Me	F	н
N	CH ₂ OH	· Me	F	Н
N	CH₂OH	Me	F	Н
N	CH ₂ OH	Me	F	Н
N	CH ₂ OH	Me	F	Н

R ₁	R ₂	R ₃	R ₄	R ₅
N N	CH ₂ OH	Me	F	Н
N N	CH ₂ OH	Me	F	н
	CH ₂ OH	Me	F	Н .
NH NW NH	CH ₂ OH	Me	F	н
N-N	CH₂OH	Me	F	н
ON	CH ₂ OH	Me	F	н .
O _N	CH ₂ OH	Me	F	Н

R ₁	R ₂	R ₃	R ₄	R ₅
S _N	CH₂OH	Me	F	н
N	CH₂OH	Me	F	Н
OM	^e CH₂OH	Me	F	Н
N	CH₂OH	Me	F	Н
ON	CH₂OH 1e	Me	F	н
Ме	Ме	Me	F	н
Ме		Me	F	Н
Me	OH	Me	F	Н

R ₁	R ₂	R ₃	R ₄	R ₅
Ме	NH ₂	Me	F	н
Ме	∕ ОН	Me	F	н
Me	∕∕∕NH₂	Me	F	Н
Me	Ph NH ₂	Me	F	н
Me	OH	Me	F	н
Ме	\sim NH ₂	Me	F	н
Me	NH ₂	Me	F	н
Me	NH ₂ CHF ₂	Me	F	н
Me	CHF ₂	Me	F	н
Me	NH ₂ CHF ₂	Me	F	H

R ₁	R ₂	R ₃	R_4	R ₅
Me	/\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\	Me	F	н
Me	A P	Me	F	Н
Me	✓ NH O	Me	F .	H
Me	N OMe	Me	F	н
Ме	NH_2	Me	F	н
Me	\sim	Me	F	н

R ₁	R ₂	R ₃	R ₄	R ₅
Me	N N	Me	F	Н
Me	NO	Me	F	н
Me	NH NH	Me	F	н
Me	√√N ^S	Me	F	Н
Me	CH₂OH		F	н
Me	CH₂OH	/	F	н

R ₁	. R ₂	R ₃	R ₄	R ₅
Me	CH₂OH	人	F	Н
Me	CH₂OH	\nearrow	F	Н
Me	CH ₂ OH		F	Н
Me	CH₂OH		F	н
Me	CH₂OH	\square	F	H
Me	CH₂OH	CN	F	н
Me	CH₂OH		F	н
Me	CH₂OH	\wedge	F	н

R ₁	R ₂	R ₃	R ₄	R ₅
Me	CH₂OH	Me	CI	н
Me	CH₂OH	Me	Br	н
Me	CH₂OH	Ме	CN	н
Me	CH₂OH	Me	Me	н
Me	CH ₂ OH	Me	CF₃	Н
Ме	CH ₂ OH	Ме	NO ₂	н
Me	CH₂OH	Ме	F	ОН
Me	CH₂OH	Me	F	NH ₂
Me	CH ₂ OH	Ме	F	F
Me	CH₂OH	Me - 164 -	F	SH

R ₁	R ₂	R ₃	R ₄	R ₅
^	CH ₂ OH	Me	F	н
/	CḤ₂OH	Ме	F	Н
	CH₂OH	Me	F	н
N	CH₂OH	Me	F	н
N	CH₂OH	Me	F	Н
N	CH₂OH	Me	F	Н
N	CH₂OH	Me	F	н

R ₁	R ₂	R ₃	R ₄	R ₅
N N	CH ₂ OH	Me	F	н
N	CH ₂ OH	Ме	F	н
	CH ₂ OH	Me	F	• н
N NH	CH₂OH	Me	F	н
N-N	CH₂OH	Me	F	н
O	CH₂OH	Me	F	н
ON	CH₂OH ·	Me	F	н

R ₁	R_2	R ₃	R ₄	R ₅
S	CH ₂ OH	Ме	F	Н
N	CH ₂ OH	Me	F	H
	OMe CH₂OH	Ме	F	Н
N	CH₂OH 〜	Me	F	Н
	I CH₂OH OMe	Ме	F	н
Me	Ме	Ме	F	Н
Me	,	Me	F	H
M	e //	OH Me	F	н

R ₁	R ₂	R ₃	R ₄	R ₅
Me	NH ₂	Me	F	Н
Ме	ОН	Me	F	Н
Me	NH ₂	Ме	F	н
Me	Ph NH ₂	Me	F	н
Ме	OH	Me	F	н
Ме	NH ₂	Me	F	н
Ме	NH_2	Me	F	Н
Me	NH ₂ CHF ₂	Me	F	н
Me	CHF ₂	Me	F	н
Ме	NH ₂ CHF ₂	Me	F	н

R ₁	R_2	R ₃	R ₄	R ₅
Me		Me	F	Н
Me	N N	Me	F	н
Me	~~NH O	Me	F	н
Me	N O OMe	Me	F	н
Me	NH ₂	Me	F	Н
Me	\sim	Me	F	Н

	D.	R_3	R ₄	R ₅
R ₁	R ₂	Me	F	Н
Ме	NO	Ме	F	Н
Me	NH NH	Ме	F	H
Ме	S N	Me	F	·H
Me	CH ₂ OH	<u></u>	F	H
Me	CH ₂ OH	<i>~</i>	F	Н

R ₁	R_2	R ₃	R ₄	R ₅
Me	CH ₂ OH	人	F	н
Me	CH₂OH	\nearrow	F	Н
Me	CH₂OH		F	н
Me	CH ₂ OH		F	н
Me	CH₂OH		F	Н
Me	CH ₂ OH	CN	F	Н
Me	CH₂OH		F	н
Ме	CH₂OH	\wedge	F	Н

R ₁	R ₂	R ₃	R ₄	R ₅
Me	CH ₂ OH	Me	Cl	Н
Ме	CH₂OH	Me .	Br	н
Ме	CH ₂ OH	Me	CN	н
Me	CH ₂ OH	Me	Me	Н
Ме	CH₂OH	Me	CF₃	н
Me	CH ₂ OH	Ме	NO ₂	н
Ме	СН₂ОН	Me	F	ОН
Me	CH₂OH	Me	F	NH ₂
Me	CH ₂ OH	Me	F	F
Ме	CH ₂ OH	Me - 172 -	F	SH

or a pharmaceutically acceptable salt or stereoisomer thereof.

14. A pharmaceutical composition that is comprised of a compound in accordance with Claim 1 and a pharmaceutically acceptable carrier.

5

15. A method of treating or preventing cancer in a mammal in need of such treatment that is comprised of administering to said mammal a therapeutically effective amount of a compound of Claim 1.

10

16. A method of treating cancer or preventing cancer in accordance with Claim 15 wherein the cancer is selected from cancers of the brain, genitourinary tract, lymphatic system, stomach, larynx and lung.

15 th

18.

17. A method of treating or preventing cancer in accordance with Claim 15 wherein the cancer is selected from histiocytic lymphoma, lung adenocarcinoma, small cell lung cancers, pancreatic cancer, gioblastomas and breast carcinoma.

20

25

from:

a compound of Claim 1 with a pharmaceutically acceptable carrier.

19. The composition of Claim 14 further comprising a second compound selected

A process for making a pharmaceutical composition which comprises combining

- 1) an estrogen receptor modulator,
 - 2) an androgen receptor modulator,
 - 3) a retinoid receptor modulator,
 - 4) a cytotoxic/cytostatic agent,
 - 5) an antiproliferative agent,
 - 6) a prenyl-protein transferase inhibitor,
 - 7) an HMG-CoA reductase inhibitor,
 - 8) an HIV protease inhibitor,
 - 9) a reverse transcriptase inhibitor,
 - 10) an angiogenesis inhibitor, and
 - 11) a PPAR-y agonist,
 - 12) a PPAR-δ agonists;

35

30

13) an inhibitor of cell proliferation and survival signaling,

WO 2005/019206

- 14) an agent that interfers with a cell cycle checkpoint, and
- 15) an apoptosis inducing agent.
- 20. The composition of Claim 18, wherein the second compound is an angiogenesis inhibitor selected from the group consisting of a tyrosine kinase inhibitor, an inhibitor of epidermal-derived growth factor, an inhibitor of fibroblast-derived growth factor, an inhibitor of platelet derived growth factor, an MMP inhibitor, an integrin blocker, interferon-α, interleukin-12, pentosan polysulfate, a cyclooxygenase inhibitor, carboxyamidotriazole, combretastatin A-4, squalamine, 6-O-(chloroacetyl-carbonyl)-fumagillol, thalidomide, angiostatin, troponin-1, and an antibody to VEGF.

10

15

inhibitor.

- 21. The composition according to Claim 14 further comprising a proteosome
- 22. The composition according to Claim 14 further comprising a aurora kinase inhibitor.
- 23. The composition according to Claim 14 further comprising a Raf kinase inhibitor.
- 20 24. The composition according to Claim 14 further comprising a serine/threonine kinase inhibitor.
 - 25. The composition according to Claim 14 further comprising an inhibitor of another mitotic kinesin which is not KSP.

25

- 26. The composition of Claim 20, wherein the second compound is an estrogen receptor modulator selected from tamoxifen and raloxifene.
- 27. A method of treating cancer which comprises administering a therapeutically effective amount of a compound of Claim 1 in combination with radiation therapy.
 - 28. A method of treating or preventing cancer that comprises administering a therapeutically effective amount of a compound of Claim 1 in combination with a compound selected from:
- 35
- 1) an estrogen receptor modulator,

		2)	an androgen receptor modulator,
		3)	a retinoid receptor modulator,
		4)	a cytotoxic/cytostatic agent,
		5)	an antiproliferative agent,
5		6)	a prenyl-protein transferase inhibitor,
		7) .	an HMG-CoA reductase inhibitor,
•		8)	an HIV protease inhibitor,
		9)	a reverse transcriptase inhibitor,
		10)	an angiogenesis inhibitor,
10		11)	PPAR-γ agonists,
	•	12)	PPAR-δ agonists,
		13)	an inhibitor of inherent multidrug resistance,
		14)	an anti-emetic agent,
		15)	an agent useful in the treatment of anemia,
15		16)	an agent useful in the treatment of neutropenia,
		17)	an immunologic-enhancing drug,
		18)	an inhibitor of cell proliferation and survival signaling,
		19)	an agent that interfers with a cell cycle checkpoint, and
		20)	an apoptosis inducing agent.
20			
		29.	A method of treating cancer that comprises administering a therapeutically
	effective amou	nt of a	compound of Claim 1 in combination with radiation therapy and a compound
	selected from:		
		1)	an estrogen receptor modulator,
25		2)	an androgen receptor modulator,
		3)	a retinoid receptor modulator,
		4)	a cytotoxic/cytostatic agent,
		5)	an antiproliferative agent,
		6)	a prenyl-protein transferase inhibitor,
30		7)	an HMG-CoA reductase inhibitor,
		8)	an HIV protease inhibitor,
		9)	a reverse transcriptase inhibitor,
		10)	an angiogenesis inhibitor,
		11)	PPAR-γ agonists,
35		12)	PPAR-δ agonists,

- 13) an inhibitor of inherent multidrug resistance,
- 14) an anti-emetic agent,

5

15

20

30

- 15) an agent useful in the treatment of anemia,
- 16) an agent useful in the treatment of neutropenia,
- 17) an immunologic-enhancing drug,
- 18) an inhibitor of cell proliferation and survival signaling,
- 19) an agent that interfers with a cell cycle checkpoint, and
- 20) an apoptosis inducing agent.
- 10 30. A method of treating or preventing cancer which comprises administering a therapeutically effective amount of a compound of Claim 1 and paclitaxel or trastuzumab.
 - 31. A method of treating or preventing cancer which comprises administering a therapeutically effective amount of a compound of Claim 1 and a GPIIb/IIIa antagonist.
 - 32. The method of Claim 31 wherein the GPIIb/IIIa antagonist is tirofiban.
 - 33. A method of treating or preventing cancer which comprises administering a therapeutically effective amount of a compound of Claim 1 in combination with a COX-2 inhibitor.
 - 34. A method of treating or preventing cancer which comprises administering a therapeutically effective amount of a compound of Claim 1 in combination with a proteosome inhibitor.
- 35. A method of treating or preventing cancer which comprises administering a therapeutically effective amount of a compound of Claim 1 in combination with an aurora kinase inhibitor.
 - 36. A method of treating or preventing cancer which comprises administering a therapeutically effective amount of a compound of Claim 1 in combination with a Raf kinase inhibitor.
 - 37. A method of treating or preventing cancer which comprises administering a therapeutically effective amount of a compound of Claim 1 in combination with a serine/threonine kinase inhibitor.

38. A method of treating or preventing cancer which comprises administering a therapeutically effective amount of a compound of Claim 1 in combination with an inhibitor of a mitotic kinesin that is not KSP.

39. A method of modulating mitotic spindle formation which comprises administering a therapeutically effective amount of a compound of Claim 1.

5

40. A method of inhibiting the mitotic kinesin KSP which comprises administering a therapeutically effective amount of a compound of Claim 1.